Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate

ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is a globally significant disease with poor survival outcomes. Immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have improved treatment paradigms, yet their real‐world efficacy and the factors influencing treatm...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Lena Huber, Constanze Kohler, Anne Lammert, Claudia Scherl, Sonja Ludwig, Annette Affolter, Nicole Rotter, Frederic Jungbauer
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2025-11-01
Sarja:	Cancer Reports
Aiheet:	head and neck squamous cell carcinoma immune checkpoint inhibitors immunotherapy response nivolumab pembrolizumab predictive biomarkers
Linkit:	https://doi.org/10.1002/cnr2.70369
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!